Ad
related to: simvastatin dosing guidelines chartgoodrx.com has been visited by 100K+ users in the past month
Ranked at No. 20 on the 2020 Disruptor 50 list. - CNBC
- Free Discount Card
Get a Free Discount Card Today and
Start Saving up to 80% Off Your Rx
- Transparent Pricing
Healthcare is confusing. We make it
simple. Use GoodRx to start saving.
- Our Social Impact Mission
At GoodRx, values matter. Visit us
to see how we make a difference.
- Find A Pharmacy Near Me
Search & Compare the Lowest Prices
to Save at Your Favorite Pharmacy
- Free Discount Card
Search results
Results from the WOW.Com Content Network
Simvastatin, sold under the brand name Zocor among others, is a statin, a type of lipid-lowering medication. [4] It is used along with exercise, diet, and weight loss to decrease elevated lipid levels. [4] It is also used to decrease the risk of heart problems in those at high risk. [4] It is taken by mouth. [4]
The statin use may require that the warfarin dose be changed, as some statins increase the effect of warfarin. [ 64 ] The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus , and increased liver enzymes in the blood due to liver damage .
An equianalgesic chart can be a useful tool, but the user must take care to correct for all relevant variables such as route of administration, cross tolerance, half-life and the bioavailability of a drug. [5] For example, the narcotic levorphanol is 4–8 times stronger than morphine, but also has a much longer half-life. Simply switching the ...
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the lipid-lowering drug niacin and the statin drug simvastatin. [1] It is used for the treatment of dyslipidemia. It was approved by the FDA on February 15, 2008. [2]
With median follow-up of 6 years, simvastatin+ezetimibe was found to reduce the primary outcome of CV mortality, major CV event, or nonfatal stroke (34.7% vs. 32.7%; P=0.016; NNT 50 per 7 years or NNT 350 per 1 year ). There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke. [6]
Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q4 2024 Earnings Call Jan 31, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred. No mutagenic effects were seen in assays.